Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/Instinet
March 15, 2018 1:45 PM EDTNomura/Instinet raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $156.00 (from $148.00) while maintaining a Buy rating.
Analyst Christopher Marai commented, "Alexion reported results from the P3 301 study of ALXN1210 in PNH-naïve patients. The study demonstrated non-inferiority across all co-primary and four key... More
Alexion Pharmaceuticals (ALXN) PT Raised to $160 at Baird
March 15, 2018 12:14 PM EDTBaird raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160.00 (from $150.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Following the call, we remain encouraged by the Phase 3 PNH naïve results with ALXN1210 demonstrating non-inferiority on all six key endpoints with... More
Alexion Pharmaceuticals (ALXN) PT Raised to $151 at Raymond James
March 15, 2018 12:13 PM EDTRaymond James raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $151.00 (from $134.00) while maintaining an Outperform rating following data today.
... MoreRBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results
March 15, 2018 9:41 AM EDTRBC Capital analsyt Kennen MacKay was positive on Alexion Pharma (NASDAQ: ALXN) after ALXN-1210 hit its hurdle in the 1st of 2 Phase 3 trials.
MacKay called the results a "win, but note a full re-rate scenario." He sees a 10-15% move.
... MoreJPMorgan Reiterates Overweight on Alexion Pharma (ALXN) Following Phase 3 Results
March 15, 2018 9:06 AM EDTJPMorgan reiterated an Overweight rating and $176.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's positive top-line results from the PNH naïve phase 3 study of ALXN1210 versus Soliris.
Analyst Anupam Rama believes that the data is "a clear win for ALXN1210 in... More
Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMO
March 15, 2018 8:57 AM EDTBMO Capital analyst M. Ian Somaiya expects shares of Alexion Pharmaceuticals (NASDAQ: ALXN) trade higher as investors breathe a sigh of relief following release of Phase 3 ALXN-1210 data.
"The treatment naïve study met most investor expectations, meeting the non-inferiority primary endpoint (some... More
